Comments
Loading...
Alaunos Therapeutics (NASDAQ:TCRT) Stock, Earnings Estimates, EPS, And Revenue
Alaunos Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
Nov 14
EPS
$-0.700
Quarterly Revenue
$0K
Annual Revenue
(as of Sep 30)
(as of Sep 30)
$7K
Analyze the earnings history of Alaunos Therapeutics using advanced sorting and filters.
Data brought to you by Benzinga APIs
Alaunos Therapeutics (TCRT) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Mar 2024 | 2024-04-01 | $-5.50 | $-4.50 | -22.2 % |
| Sep 2023 | 2023-11-14 | $-6.00 | $-4.50 | -33.3 % |
| Jun 2023 | 2023-08-14 | $-6.00 | $-6.00 | 0.00 % |
| Mar 2023 | 2023-05-10 | $-6.00 | $-6.00 | 0.00 % |
Alaunos Therapeutics (TCRT) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
FAQ
When is Alaunos Therapeutics (NASDAQ:TCRT) reporting earnings?
Alaunos Therapeutics ({quoteSymbol}) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 14, 2024 for Q3.
What were the latest earnings per share (EPS) for Alaunos Therapeutics (NASDAQ:TCRT)?
Alaunos Therapeutics ({quoteSymbol}) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 14, 2024 for Q3 and the Actual EPS was $-0.70, which missed the estimate of $0.00.
What were Alaunos Therapeutics’s (NASDAQ:TCRT) revenues?
Alaunos Therapeutics ({quoteSymbol}) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 14, 2024 for Q3 and the Actual EPS was {{actualEPS}}, which hit the estimate of {{estEPS}}.
Browse earnings estimates, EPS, and revenue on all stocks.